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Abstract 
Background: 
Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3 and CA125, and 
generate antibodies against them; but their impact on epithelial ovarian cancer (EOC) risk has 
not been fully defined.            
Methods: 
CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who 
developed EOC and 1,927 matched controls from the European Prospective Investigation of 
Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies 
were evaluated using generalized linear models; EOC risks associated with anti-mucin 
antibodies, by themselves or in combination with respective antigens, were evaluated using 
conditional logistic regression. 
Results: 
In controls, lower antibodies against both mucins were associated with current smoking; and, in 
postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and 
shorter-interval-since last birth.  Lower anti-CA15.3 antibodies were associated with higher body 
mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-
CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from 
enrollment.  Long-term risk for serous EOC was reduced in women with low CA125 and high 
anti-CA125 antibodies relative to women with low concentrations of both.               
Conclusions: 
We found general support for the hypothesis that anti-mucin antibody levels correlate with risk 
factors for EOC.  Antibodies alone or in combinations with their antigen may predict longer term 
risk of specific EOC types.     
Impact:  
Anti-CA125 and anti- CA15.3 antibodies alone or in perspective of antigens may be informative 
in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC. 
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Introduction 
 
In the 1980s, two heavily-glycosylated proteins were discovered as potential markers for breast 
and epithelial ovarian cancer(EOC)(1, 2). Monoclonal antibodies were raised against selected 
epitopes and assays developed whose names became synonymous with the markers CA15.3 for 
the breast biomarker and CA125 for the EOC biomarker. Genes for these proteins were 
eventually cloned and proved to be members of the human mucin family(3, 4) - CA15.3 as 
human mucin 1 (MUC1) and CA125 as human mucin 16 (MUC16).  Both proteins were found to 
be expressed on mucosal barriers lining the genital, digestive, and respiratory tracts and breast 
ducts and over expressed in many of the neoplasms originating from these tissues (5, 6).  
Specifically, for invasive EOC and depending upon the antibody used for histochemical analysis, 
a majority of all EOC subtypes express CA15.3(7). Tissue expression of CA125 varies by 
subtype from 12% (mucinous) to 85% (serous)(8).  Higher serum levels of CA15.3 in patients 
with breast and colorectal cancers were associated with poorer prognosis(9, 10) and thought to 
reflect an immunosuppressive effect on T cell proliferation(11). Similarly, in EOC, high serum 
levels of CA125 predict advanced disease and poorer survival(12). Like CA15.3, this may have 
an immune basis since CA125 can bind with natural killer(NK) cells and blunt NK response to 
ovarian tumors cells(13).   
Antibodies against CA15.3 and CA125 have also been described. Anti-CA15.3 antibodies were 
found in some in patients with CA15.3-expressing cancers and associated with better prognosis 
(14).  Both CA15.3 and anti-CA15.3 antibodies can also be found in healthy women, including 
those who are pregnant or breastfeeding(15). This led to the theory that anti-CA15.3 antibodies 
evoked by these events could explain why they protect against breast cancer(16). CA125 is 
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elevated in pregnancy, but whether anti-CA125 antibodies also form during pregnancy has not 
been studied.   However, events which reduce EOC risk like pelvic surgery, mumps, or puerperal 
mastitis, may lead to elevated (and presumably protective) levels of both anti-CA125 and anti-
CA15.3 antibodies(17-20). Conversely, chronic events that increase EOC risk like repeated 
damage and repair to the ovary from “incessant ovulation” (ovulations not interrupted by 
pregnancy or oral contraceptive use) were associated with lower levels of anti-CA15.3 
antibodies, suggesting immune tolerance that allows emergence of a CA15.3-expressing 
cancer(20, 21). These observations form the basis for a general paradigm that risk factors for 
mucin-expressing cancers may operate because of humoral (and, likely, cellular) immune 
reactions to mucin-expression invoked by the events themselves. Chronicity of the exposure may 
determine whether the event raises or lowers risk for the cancer. 
In this study, we measured anti-CA15.3 and anti-CA125 antibodies and their corresponding 
antigens in sera from female participants in the European Prospective Investigation of Nutrition 
and Cancer(EPIC) including 806 who subsequently developed invasive EOC and 1,927 matched 
controls. We sought to identify factors associated with levels of anti-CA15.3 and anti-CA125 
antibodies by menopausal status and determine whether these antibodies were associated with 
early detection (elevated levels within three years of diagnosis) or risk (elevated levels three or 
more years before diagnosis) of EOC overall and by histologic subtypes.     
Material and Methods 
The EPIC cohort – background and collection of blood samples 
EPIC is an ongoing multicenter prospective cohort study designed to investigate relationships 
between diet and cancer(22). Briefly, 519,978 participants (366,521 women) were enrolled from 
1992 to 2000 in 23 centers in 10 European countries: Denmark, France, Germany, Greece, Italy, 
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Norway, the Netherlands, Spain, Sweden, and the United Kingdom. A total of 385,747 
participants (226,673 women) provided a baseline blood sample, kept frozen in long-term 
storage at ≤-150oC, with the exception of Sweden, where samples are stored at -70oC. 
Ascertainment of incident cancer cases 
Cancer occurrence was documented through record linkage with cancer registries or active 
follow-up.  Self-report was verified by clinical record review. Vital status was determined by 
linkage with mortality registries. When the present study was initiated, follow-up was complete 
through 2005 (France) to 2008 (Germany). Among women who had provided a baseline blood 
sample, a total of 806 incident cases of invasive EOC were identified including ovary 
(International Classification of Diseases for Oncology (ICD) O–3code: C569), fallopian tube 
(C570) or peritoneal cancer (C480, C481, C482, C488).  Low malignant potential (borderline) 
tumors were not included. For the 806 EOC cases, complete information on tumor grade was 
available for 471 patients (58%) and information on tumor stage was available for 709 patients 
(88%).   
Design of nested case-control study 
For each case, up to four controls were randomly selected from female cohort members who 
were alive and cancer-free at diagnosis of the index case using a sampling protocol described 
previously(23). Case and control participants were matched on study center, age at blood 
donation, time of the day of blood collection, fasting status, menopausal status, menstrual cycle 
phase for premenopausal women, current use of oral contraceptives(OC) or hormonal 
replacement therapy (HRT).     
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Exposure Data 
Baseline data were self-reported through questionnaires or interview except for body mass index 
(BMI) where height and weight were directly measured. Categorized, the variables included: age 
at blood draw (<41, 41-50, 51-60, 61-70, >70 years), BMI (<18.5, 18.5-24.99, 25-29.99, ≥30 
kg/m
2
), smoking (never, former, current), pack years (≤11, 12-19, 20-31, >31), age at menarche 
(<12, 12, 13, 14, >14), OC use (never/ever), OC duration (≤2, >2-5, >5-10, >10 years), number 
(0, 1, 2, 3, 4+) and timing of pregnancies, age at first birth (<20, 20-24, 25-29, ≥30), age at last 
birth (<25, 25-29, 30-34, ≥35), years since last birth (<21, 21-27, 28-32, >32 years), 
hysterectomy, oophorectomy, family history of breast cancer, age at menopause (<46, 47-49, 50-
51, 52-53, >53), and HRT use (postmenopausal never used HRT, ≤2.5 years, >2.5 years). The 
number of ovulatory cycles was estimated by calculating years between menarche and current 
age or age at menopause (if postmenopausal) and subtracting time using oral contraceptives, 
pregnant, or breastfeeding.  Those missing an exposure of interest were excluded from analyses 
for that exposure.       
Laboratory Methods 
Assays were performed at the Brigham and Women’s Hospital Laboratory of Genital Tract 
Biology using a multiplex platform (Meso Scale Discovery, MSD). Laboratory personnel were 
blind to case-control and quality-control sample status. Methods related to the measurement of 
CA125 and CA15.3 were previously described(23). Similar batching rules used for the mucin 
antigens were employed for the mucin antibodies; i.e. keep matching pairs together and as many 
from the same center as possible with at least 6 QC samples. The following reagents were 
provided by Fujirebio Diagnostics, Inc. (Malvern, PA): anti-CA125 antibody, anti-CA15.3 
antibody. To measure antibodies against CA15.3 and CA125, antigen-grade CA15.3 and CA125 
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purified from human breast and ovarian cancer cell lines (Meridian Life Sciences Inc., Memphis, 
TN) were coated on multi-spot plates. The assays included blocking with a blocking buffer for 
1h followed by wash; 2h incubation with samples at multiple dilutions followed by PBS/0.05% 
Tween-20 wash; detection of human IgG1 bound to the specific protein spots with MSD sulfo-
Tag-labeled antibodies (1µg/ml) for 2h; washing and adding read buffer followed by detection of 
electro-chemiluminescence (ECL) using an MSD Imager 2400. Split aliquots of this pool were 
tested at the same dilutions as the test samples on each assay plate and served to assess inter-
batch variation. Coefficients of variation were calculated using measurements from blinded 
aliquots. Average intra-plate CVs were 14% for anti-CA125, 11% for anti-CA15.3, and the inter-
plate CVs were 35% and 31%, respectively. 
Statistical analyses 
To account for batch-to-batch variation, we recalibrated antibodies to have a comparable 
distribution to an average batch according to methods described by Rosner and colleagues(24).  
Other than batch number, no other variables were used in the recalibration models. Anti-CA15.3 
and anti-CA125 antibody levels were log-transformed (as were CA15.3 and CA125).  
Correlation between antigens and antibodies was assessed using Spearman partial correlations 
adjusted for the study matching factors. We used generalized linear models to estimate mean 
antibody values separately in controls and cases overall and by menopausal status since risk 
factors, especially reproductive variables, may differ by menopausal status(25). Results were 
exponentiated to obtain geometric mean values in the original scale. Linear regression models 
were adjusted for the study matching factors, BMI, and smoking status.  Indicators were used to 
account for missing data for covariates.  Trend tests of continuous variables were based on the 
medians of each category. We included interaction terms in the linear regression models to test 
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for heterogeneity in antibody levels by menopausal status.  To examine the associations between 
antibodies and ovarian cancer, we classified antibodies into quartiles based on the control 
distribution and calculated odds ratios and 95% confidence intervals (CI) using conditional 
logistic regression. In the conditional logistic regression analyses, we individually added each 
potential confounder to the model and examined the change in the OR estimate from the crude 
OR.  The covariates examined were age at menarche, OC use, parity, hysterectomy, 
oophorectomy, duration of HRT use, BMI, and smoking status (using categories described 
above).  The percent changes in the adjusted ORs from the crude ORs were minimal, ranging 
from 0-3%, therefore we present crude conditional logistic regression results. We evaluated risk 
associations separately for cases diagnosed within three years (to reflect early detection) and 
greater than three years (to reflect risk); these lag-time cutpoints were based on prior studies in 
the EPIC cohort(23) and by others(20, 26).  Finally, using median values as cutpoints, we cross 
classified participants as having high or low antibodies and antigens and examined the 
association between these biomarker combinations and ovarian cancer. We used the contrast test 
method to test whether the association between increasing antibodies and risk, and between 
antigen-antibody combination and risk, varied by histologic type(27). Analyses were conducted 
using SAS version 9.4 (Cary, NC). Statistical tests were two-tailed and significant at p<0.05. 
Informed consent and data protection 
All participants gave consent for future analyses of their blood samples in their written consent. 
The principles expressed in the Helsinki Declaration of 1996, conventions of the Council of 
Europe on Human Rights and Biomedicine, and the UNESCO Declaration on Human Genome 
have been respected. The present study was approved by the ethics committees at the 
International Agency for Research on Cancer(IARC) and the University of Heidelberg 
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(Germany). Since the identity of subjects providing specimens was anonymous to Brigham and 
Women’s Hospital (BWH) investigators, the research was declared exempt at BWH.     
 Results 
Table 1 compares the characteristics of EOC cases and controls in this nested case-control study.  
Cases did not differ from controls in age at enrollment or menopausal status, but were more 
likely to be heavier, nulliparous, and to have never used oral contraceptives (and used oral 
contraceptives for a shorter duration). Concentrations of anti-CA15.3 antibodies by 
epidemiologic variables in all, premenopausal, and postmenopausal controls are shown in Table 
2. Among postmenopausal women, we observed higher anti-CA15.3 antibodies with older age at 
baseline (Ptrend=0.04).  Overall, anti-CA15.3 antibodies were lower among women with higher 
BMI (Ptrend=0.03) and current smoking (P<0.0001). Among current smokers, more pack-years 
were associated with lower anti-CA15.3 antibodies (Ptrend=0.002). Among women 
premenopausal at baseline, ever versus never use of OCs was associated with lower anti-CA15.3 
antibodies (P=0.05); and higher number of ovulatory cycles was associated with a trend for 
lower anti-CA15.3 antibodies (Ptrend=0.02). Among postmenopausal women, higher anti-CA15.3 
antibodies were associated with later age at last birth (Ptrend=0.02), shorter interval since last birth 
(Ptrend=0.04), and longer duration of OC use (Ptrend=0.01).  The difference in the trend in anti-
CA15.3 antibody levels by duration and OC use between pre- and postmenopausal women was 
significant (P for heterogeneity = 0.03).  
Similar to associations seen for anti-CA15.3 antibodies, current smoking was associated with 
lower anti-CA125 antibodies (P<0.0001), and among smokers, anti-CA125 levels declined with 
increasing pack-years (Ptrend=0.004) (Table 3). Among postmenopausal women, later age at last 
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birth (Ptrend=0.002) and shorter interval since last birth (Ptrend=0.005) were associated with higher 
anti-CA125 antibodies. Among premenopausal women, duration of OC use was associated with 
a lower level of anti-CA125 antibodies when non-users were included in the referent non-
exposed category.    
Among cases, we observed no associations between tumor characteristics and antibody levels 
(Supplemental Table 1). When we evaluated all cross-sectional associations adjusting for the 
corresponding antigen concentration, results were unchanged. Other variables that were 
examined and found not to affect anti-mucin antibodies in either cases or controls included: 
miscarriage, hysterectomy or unilateral oophorectomy, family history of breast cancer, IUD use, 
and duration of HRT use. Information on tubal sterilization was not collected at all EPIC sites 
and data was too limited to evaluate this exposure.      
We then evaluated quartiles of anti-CA15.3 and anti-CA125 antibodies and EOC risk in all 
subjects and subjects stratified by menopausal status at blood collection, histologic type of EOC, 
and time between blood collection and diagnosis (<3 years and ≥3 years) (Table 4). For 
mucinous EOC arising three or more years after baseline, trends for increased risk were found 
with both increasing anti-CA15.3 antibodies (Ptrend=0.02) and increasing anti-CA125 antibodies 
(Ptrend=0.05).  Of borderline significance, there was a trend for higher levels of anti-CA15.3 
antibodies to be associated with lower risk for serous EOC (Ptrend=0.06) that developed within 3 
years of their blood draw.  Levels of anti-CA15.3 in the fourth quartile were associated with an 
OR (and 95% CI) of 0.51 (0.27, 0.96) compared to women with levels in the first quartile.    
Next, we evaluated risk for EOC by anti-CA15.3 and anti-CA125 antibody levels jointly 
classified by the corresponding antigen level with both dichotomized as high or low based on 
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median cutpoints in controls (Table 5). Although combining CA15.3 antigen levels with anti-
CA15.3 antibody levels was not informative, combining CA125 levels with anti-CA125 antibody 
yielded several interesting findings. Relative to women with low concentrations of both markers, 
EOC risk overall was elevated for women with high CA125 levels regardless of anti-CA125 
antibody levels, but only for disease arising within 3 years of blood draw. These effects were 
most apparent in postmenopausal women and those with serous or endometrioid EOC.  
Conversely, a reduction in risk for all EOC, both in short and long-term risk was associated with 
low CA125 antigen and high anti-CA125 antibody. For women who developed serous EOC, the 
combination of low CA125 antigen and high anti-CA125 antibody was associated with an OR 
(and 95% CI) of 0.60 (0.40, 0.89) for disease that developed more than 3 years after blood draw.  
Anti-CA15.3 and anti-CA125 antibodies were strongly correlated in cases (r=0.75, P<0.0001) 
and controls (r=0.75, P<0.0001. In all premenopausal EOC cases, there was a weak but 
significant inverse correlation between CA15.3 and anti-CA15.3 antibodies of -0.15 (P=0.04) 
that was strongest for premenopausal serous cases r=-0.34 (P=0.001).  In all EOC cases, there 
was a weak but significant positive correlation between CA125 and anti-CA125 antibodies of 
0.10 (P=0.004) that was strongest for mucinous tumors r=0.40 (P=0.01). Overall, no significant 
correlations were noted between anti-mucin antibodies and their corresponding antigen in 
controls (Table 6).  
  
Discussion 
We examined levels of IgG1 anti-CA15.3 and IgG1 anti-CA125 antibodies in baseline 
specimens from women who went on to develop EOC and matched controls from the EPIC 
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cohort. We sought to identify those epidemiologic factors in control subjects that were associated 
with anti-mucin antibody levels. Our general premise was that events known to increase (or 
decrease) EOC risk will be those that decrease (or increase) anti-CA15.3 or anti-CA125 antibody 
levels. Using both case and control participants, we then sought to determine whether anti-
CA15.3 or anti-CA125 antibodies, either by themselves or considered in the context of the 
corresponding antigen, were associated with EOC risk.   
Because of their importance as correlates of EOC risk, the effect of reproductive variables on 
antibody levels were of principal interest. Decreased EOC risk with increasing parity and 
duration of OC use are two consistent epidemiologic findings. No clear effect of higher parity on 
either anti-CA15.3 or anti-CA125 antibody levels was seen, although longer duration of OC use 
was associated with higher anti-CA15.3 antibody levels (Ptrend=0.01) in postmenopausal women. 
There is clear evidence that a later age at last birth (and a shorter interval since last birth) lowers 
EOC risk (25). Among postmenopausal women, but not premenopausal women, we observed 
higher levels of both anti-CA15.3 and anti-CA125 antibodies to be associated with a later age at 
and shorter interval since last birth. These late reproductive events are clearly set for 
postmenopausal women but may not be for premenopausal controls in EPIC. Both observations 
suggest that anti-CA125 antibodies may be generated during pregnancy, as has been reported for 
anti-CA15.3(15) antibodies, and wane with time since pregnancy.   
We observed that lower anti-CA15.3 antibodies were associated with a higher number of 
ovulatory cycles in control subjects who were premenopausal at blood donation. This 
observation confirms an inverse correlation between anti-CA15.3 antibodies and ovulatory 
cycles seen in two other independent studies(20, 21) and is again consistent with the proposition 
that low antibodies predict greater risk since an increasing number of estimated ovulatory cycles 
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is associated with increasing EOC risk(28-30).  On the other hand, La Vecchia etal(31) expressed 
doubts about disentangling independent effects of the components of the algorithm used to 
construct the estimate (i.e. age at menarche, number of pregnancies, duration of OC use or 
breastfeeding, and current age or age at menopause). Particularly for premenopausal women, 
current age is an obvious confounder since older women will have a greater number of potential 
ovulatory years than younger women.  However, the association we observed between ovulatory 
cycles and anti-CA15.3 antibodies seen in the linear regression models included continuous age 
as an adjustment variable. That the association was confined to premenopausal women is 
compatible with the observation that ovulatory cycles are a stronger predictor of EOC risk in 
premenopausal women than in postmenopausal women(30). Indeed, Purdie et al. proposed that 
more ovulations during ages 20-29 were the strongest predictor of greater EOC risk(29).     
The lack of association between ovulatory cycles and anti-CA15.3 antibodies in postmenopausal 
women in our study and weak correlation of ovulatory cycles with EOC risk in postmenopausal 
women in published studies could reflect poorer recall of early reproductive events in 
postmenopausal women. Alternatively, the transition to menopause may take several years 
during which anovulatory cycles are common; therefore, the assumption that ovulation occurs 
regularly until menopause would introduce error in calculating ovulatory cycles for 
postmenopausal women.   
Age, BMI, and smoking were non-reproductive variables that influenced antibody levels.  Anti-
CA15.3 antibodies increased with older age and declined with higher BMI. The latter 
observation is compatible with the fact that high BMI may increase risk for EOC, as well as 
other CA15.3-expressing cancers including endometrial cancer and postmenopausal breast 
cancer(32).  Current smoking was associated with both lower anti-CA15.3 and anti-CA125 
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antibodies and levels decreased further with increasing pack-years.  Smoking does not appear to 
affect risk for EOC overall but is associated with increased risk of mucinous EOC(33, 34). The 
observation that smoking lowers anti-CA15.3 antibodies and increases risk for mucinous tumors 
fits with our hypothesis regarding how risk factors may operate; but not our hypotheses that 
higher levels of antibodies lowers the risk for EOC in general.  This may relate to the uniqueness 
of mucinous tumors compared to the other subtypes. 
Despite finding general support for our premise that anti-CA15.3 and anti-CA125 antibodies 
may correlate with risk factors for EOC, we found no evidence that, by themselves, they 
predicted risk for EOC overall; but they may predict risk for specific histologic types of EOC. 
Thus, we found higher levels of both anti-CA15.3 and anti-CA125 antibodies were associated 
with higher risk for mucinous tumors developing three or more years after baseline, though our 
numbers for this rarer subtype were limited, especially cases developing mucinous tumor 
premenopausally. As mentioned above this finding is contrary to our original hypothesis that 
anti-mucin antibodies may decrease risk for EOC, but may be explained by the similarities of 
mucinous ovarian tumors to colorectal cancers (CRC) which have been described(35). This is of 
interest in that a study looking at the ability of MUC1 auto-antibodies to predict risk for CRC in 
prospective specimens from United Kingdom Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) found that elevated levels predicted greater risk for CRC with a lead time of at 
least 2 years(36).   
In our study, we found a modest trend (P=0.06) for a greater level of anti-CA15.3 antibodies to 
be associated with lower risk for serous ovarian cancer developing within 3 years of baseline; but 
no effect on long-term risk.  The ability of anti-CA15.3 antibodies to predict risk for EOC was 
previously addressed in the Nurses’ Health Studies(20). This study excluded cases diagnosed 
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within three years to focus on longer term risk.  In the NHS, higher levels of anti-CA15.3 
antibodies decreased EOC risk in women who were <64 at blood draw but increased risk for 
women who were > 64 at blood draw. We examined age 64 as a cutpoint for long-term risk in the 
current study, but did not confirm the NHS finding. In the NHS, antibodies against an 
unglycosylated tandem repeat were measured while antibodies against intact CA15.3 were 
measured in this study. The ability of anti-MUC1 antibodies to aid in the early detection of EOC 
overall was also addressed in the UKCTOCS study. In this study, antibodies were measured 
against various glycopeptide “pieces” of MUC1 and recombinant (unglycosylated) MUC1 
containing the 16 tandem repeats. Antibody reactivity to MUC1 tandem repeat peptides or 
glycoforms did not differ between controls and EOC cases, nor cases with other MUC1-
expressing cancers, including breast, lung, and pancreas(37).   
Neither the NHS nor UKCTOCS examined the combined effect of antigen and antibody levels as 
done in this study.  Several new findings emerged in the current study with respect to both short 
and long-term risk for EOC, primarily related to CA125 antigen and its antibody.  High CA125 
levels, regardless anti-CA125 antibody level, predicted increased short-term risk for all EOC, 
EOC arising postmenopausally, and serous EOC. This is not surprising since both EPIC(23) and 
other prospective studies(38,39) reported elevated CA125 is the strongest predictor of EOC 
development within a year of the blood draw, but diagnostic discrimination wanes rapidly with 
lag-times between blood collection and diagnosis of more than 1 to 2 years. Perhaps more 
important is our novel observation that the combination of low CA125 and high anti-CA125 
antibodies lowers risk for all EOC in both the long and short-term and for serous EOC in the 
long-term. The contribution of anti-CA125 antibody levels to CA125 in early detection is 
explored more fully in a separate publication(40).   
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Limitations of our study are that standards for anti-CA15.3 or anti-CA125 antibody assays have 
not been established both in terms of antigen epitope to be used and which phenotype, IgG or 
IgM, to measure. In particular, epitopes used may be based on unique peptide sequences or the 
whole protein in either glycosylated or unglycosylated forms. It has been postulated that mucin 
antigens shed by inflammatory or hormonal events may be less glycosylated than unshed mucins 
and more similar to mucins shed by a tumor, but precise differences are unclear as well as 
whether anti-mucin antibodies formed in response to tumor mucins differ from those formed 
from non-neoplastic events. It is also possible that complexes involving the mucin antigens and 
antibodies can form which could hide the mucin antigen from its detection assay and be relevant 
to EOC cases presenting with low CA125(41). Finally, results of these analyses should be 
considered in the context of the number of tests performed and possibility of chance findings, 
particularly for subgroup analyses in which numbers are limited. 
In conclusion, we found some support for our premise that events known to increase (or 
decrease) EOC risk generally correlate with those that decrease (or increase) anti-CA15.3 or anti-
CA125 antibody levels. Although by themselves, anti-mucin antibodies were not strongly 
associated with overall EOC, higher levels of both anti-CA15.3 and anti-CA125 were associated 
with greater longer term risk for mucinous EOC. This might reflect the similarities of mucinous 
tumors to CRC where higher anti-MUC1 antibodies predict greater, not lower, risk. Not 
surprisingly, high CA125 regardless of anti-CA125 antibodies predicted higher risk for EOC in 
the short-term especially for women who developed serous EOC. Notably, the combination of 
low CA125 and high anti-CA125 antibodies is associated with lower long-term risk for serous 
EOC; i.e. disease developing 3 or more years after baseline. The latter observation may be more 
useful in defining the role of CA125 in the pathogenesis of serous EOC and less so for 
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improving early detection. Advancing this research will require a greater understanding of the 
biology and immunology of CA125 and CA15.3, the nature of the antibodies that develop 
against them, and how they interact with traditional risk factors for EOC.   
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Table 1.  Characteristics of cases and controls in the EPIC ovarian nested case-control study. 
 
 Controls 
N=1927 
Cases 
N=806 
Age at blood draw (years)   
   Mean (SD) 56.2 (8.3) 56.1 (8.1) 
Menopausal status, N (%)   
   Premenopausal 485 (25.5%) 201 (25.4%) 
   Postmenopausal 1416 (74.5%) 589 (74.6%) 
BMI   
   Mean (SD) 25.8 (4.5) 26.1 (4.8) 
Smoking status, N (%)   
   Never 1096 (57.9%) 429 (54.3%) 
   Former 431 (22.8%) 185 (23.4%) 
   Current 367 (19.4%) 176 (22.3%) 
Oral contraceptive use, N (%)   
   Never 924 (49.8%) 431 (55.7%) 
   Ever 933 (50.2%) 343 (44.3%) 
Duration of oral contraceptive use   
   Mean (SD) 8.5 (8.1) 7.0 (7.0) 
Parity, N (%)   
   Nulliparous 202 (11.3%) 129 (17.3%) 
   Parous 1579 (88.7%) 616 (82.7%) 
Number of births among parous women   
   Mean (SD) 2.4 (1.1) 2.3 (1.1) 
Ovulatory cycles   
   Mean (SD) 406.1 (64.4) 412.2 (62.2) 
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Table 2. Associations between epidemiologic characteristics and anti-CA15.3 antibodies in healthy controls, stratified by menopausal status. 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
Age at blood draw (years) 
          
  
  < 41  75 (4) 8253 (5569, 12232) 0.97 
 
75 (15) 7802 (5467, 11134) 0.78 
 
0 (0) -- 
 
  
  41-50 327 (17) 8188 (6747, 9936) Ref. 
 
269 (55) 7372 (6183, 8789) Ref. 
 
47 (3) 9571 (6066, 15100) Ref.   
  51-60 853 (44) 7464 (6714, 8298) 0.43 
 
141 (29) 6751 (5138, 8870) 0.62 
 
697 (49) 7664 (6801, 8638) 0.35   
  61-70 585 (30) 9257 (8118, 10555) 0.34 
 
0 (0) -- -- 
 
585 (41) 9543 (8384, 10862) 0.99   
  > 70 87 (5) 10135 (7181, 14302) 0.30 
 
0 (0) -- -- 
 
87 (6) 10758 (7476, 15481) 0.70   
  ptrend   
0.07 
   
0.55 
   
0.04   
  
           
  
BMI (kg/m2) 
           
  
  <18.5  30 (2) 11362 (6597, 19571) 0.35 
 
9 (2) 7718 (3064, 19441) 0.93 
 
21 (2) 12090 (6193, 23605) 0.39  0.77 
  18.5-24.99 872 (48) 8715 (7865, 9656) Ref. 
 
267 (59) 8063 (6822, 9529) Ref. 
 
589 (44) 8946 (7867, 10174) Ref.  Ref. 
  25 - 29.99 658 (36) 8092 (7204, 9091) 0.36 
 
131 (29) 6513 (5125, 8277) 0.16 
 
522 (39) 8658 (7570, 9902) 0.73  0.18 
  >=30 271 (15) 7065 (5858, 8521) 0.06 
 
46 (10) 6165 (4101, 9267) 0.24 
 
222 (16) 7425 (5983, 9214) 0.16  0.60 
  ptrend   
0.03 
   
0.15 
   
0.12  0.41 
  
           
  
Smoking 
           
  
  Never 1096 (58) 9012 (8232, 9865) Ref. 
 
273 (57) 7830 (6632, 9245) Ref. 
 
816 (59) 9439 (8470, 10520) Ref.  Ref. 
  Former 431 (23) 8855 (7664, 10230) 0.84 
 
114 (24) 7872 (6051, 10242) 0.97 
 
310 (22) 9181 (7701, 10945) 0.8  0.88 
  Current 367 (19) 5782 (4942, 6764) <0.0001 
 
94 (20) 5168 (3869, 6902) 0.02 
 
266 (19) 6123 (5058, 7413) 0.0002  0.98 
  
           
  
Packyears (among current smokers) 
          
  
  <=11 packyears 89 (25) 9069 (6836, 12031) Ref. 
 
34 (37) 7737 (5203, 11505) Ref. 
 
53 (21) 10459 (7140, 15321) Ref.  Ref. 
  12-19 91 (25) 5443 (4114, 7202) 0.01 
 
21 (23) 4183 (2502, 6991) 0.08 
 
67 (26) 5695 (4008, 8091) 0.03  0.88 
  20-31 95 (27) 4216 (3231, 5502) 0.0002 
 
26 (28) 4604 (2914, 7275) 0.11 
 
68 (26) 4370 (3146, 6070) 0.0009  0.63 
  >31 82 (23) 4716 (3505, 6345) 0.002 
 
12 (13) 3070 (1582, 5956) 0.03 
 
69 (27) 4998 (3569, 6998) 0.005  0.82 
  ptrend   
0.002 
   
0.02 
   
0.008  0.87 
  
           
  
Age at menarche (years) 
          
  
  < 12 266 (14) 7531 (6243, 9084) 0.77 
 
93 (20) 5632 (4196, 7561) 0.8 
 
171 (13) 8528 (6708, 10842) 0.56  0.76 
  12 352 (19) 7260 (6191, 8513) Ref. 
 
94 (20) 5940 (4440, 7948) Ref. 
 
257 (19) 7789 (6432, 9434) Ref.  Ref. 
  13 422 (23) 8395 (7263, 9703) 0.19 
 
118 (26) 9347 (7227, 12089) 0.02 
 
301 (22) 8214 (6886, 9797) 0.69  0.15 
  14 433 (24) 8550 (7405, 9873) 0.14 
 
94 (20) 7934 (5918, 10638) 0.18 
 
336 (25) 8836 (7474, 10445) 0.33  0.58 
  > 14 365 (20) 8883 (7584, 10405) 0.08 
 
60 (13) 6940 (4820, 9994) 0.52 
 
299 (22) 9426 (7879, 11277) 0.16  0.63 
  ptrend   
0.07 
   
0.13 
   
0.23  0.82 
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Table 2. Associations between epidemiologic characteristics and anti-CA15.3 antibodies in healthy controls, stratified by menopausal status. (continued) 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
Oral contraceptive use 
           
  
  Never 924 (50) 7947 (7156, 8826) Ref. 
 
145 (31) 8831 (6880, 11334) Ref. 
 
775 (56) 8040 (7159, 9029) Ref.  Ref. 
  Ever 933 (50) 8408 (7575, 9332) 0.48 
 
320 (69) 6434 (5487, 7546) 0.05 
 
604 (44) 9371 (8199, 10711) 0.11  0.08 
  
           
  
  <= 2 years 257 (14) 8002 (6630, 9658) Ref. 
 
101 (22) 7675 (5743, 10256) Ref. 
 
153 (12) 8034 (6270, 10294) Ref.  Ref. 
  > 2 to 5 years 180 (10) 6530 (5221, 8165) 0.15 
 
68 (15) 5093 (3603, 7200) 0.11 
 
111 (8) 6950 (5189, 9309) 0.39  0.37 
  > 5  to 10 years 207 (12) 9107 (7370, 11252) 0.43 
 
77 (17) 6278 (4527, 8705) 0.26 
 
127 (10) 10867 (8241, 14329) 0.13  0.09 
  > 10 years 225 (13) 9451 (7668, 11650) 0.32 
 
62 (14) 5971 (3993, 8929) 0.46 
 
161 (12) 11152 (8683, 14324) 0.14  0.04 
  ptrend
† 
  
0.09 
   
0.24 
   
0.01  0.06 
  ptrend
§ 
  
0.11 
   
0.78 
   
0.06  0.03 
  
           
  
Parity 
           
  
 Nulliparous 202 (11) 7725 (6268, 9521) Ref. 
 
48 (11) 5577 (3689, 8432) Ref. 
 
152 (12) 8511 (6642, 10905) Ref.  Ref. 
 Parous 1579 (89) 8339 (7742, 8982) 0.5 
 
406 (89) 7366 (6425, 8445) 0.22 
 
1162 (88) 8781 (8032, 9598) 0.82  0.36 
pdiff            
  
  1 child 277 (16) 8308 (6938, 9948) Ref. 
 
74 (17) 6452 (4630, 8993) Ref. 
 
200 (15) 9197 (7396, 11438) Ref.  Ref. 
  2 children 730 (42) 7960 (7128, 8891) 0.69 
 
215 (50) 8085 (6666, 9805) 0.33 
 
512 (40) 7959 (6948, 9118) 0.29  0.13 
  3 children 348 (20) 9728 (8297, 11406) 0.19 
 
75 (17) 7237 (5212, 10049) 0.77 
 
270 (21) 10523 (8741, 12669) 0.34  0.98 
  4+ children 180 (10) 8346 (6636, 10496) 0.92 
 
22 (5) 9049 (4872, 16805) 0.36 
 
157 (12) 8508 (6612, 10949) 0.66  0.27 
  ptrend
† 
  
0.22 
   
0.13 
   
0.52  0.65 
  ptrend
§ 
  
0.31 
   
0.55 
   
0.52  0.31 
  
           
  
Age at first birth (years) 
          
  
  <20 120 (8) 8234 (6247, 10852) Ref. 
 
28 (7) 7934 (4573, 13765) Ref. 
 
90 (8) 8148 (5870, 11311) Ref.  Ref. 
  20-24 683 (43) 7931 (7075, 8890) 0.81 
 
179 (44) 7221 (5842, 8925) 0.76 
 
500 (43) 8281 (7222, 9496) 0.93  0.67 
  25-29 543 (34) 8784 (7726, 9987) 0.68 
 
140 (34) 8352 (6559, 10636) 0.87 
 
399 (34) 8958 (7679, 10450) 0.61  0.85 
  ≥30 228 (14) 8460 (6934, 10321) 0.88 
 
59 (15) 5274 (3605, 7717) 0.23 
 
168 (15) 10080 (7951, 12779) 0.31  0.11 
  ptrend   
0.48 
   
0.3 
   
0.15  0.11 
  
           
  
Age at last birth (years) 
          
  
  <25 217 (14) 7313 (5962, 8971) Ref. 
 
64 (17) 7442 (5181, 10688) Ref. 
 
150 (13) 7319 (5693, 9409) Ref.  Ref. 
  25-29 532 (35) 8166 (7173, 9297) 0.37 
 
137 (35) 8639 (6762, 11038) 0.51 
 
394 (35) 7906 (6770, 9233) 0.61  0.63 
  30-34 508 (33) 8552 (7492, 9763) 0.21 
 
133 (34) 5933 (4646, 7577) 0.31 
 
369 (33) 9820 (8372, 11518) 0.05  0.07 
  ≥35 273 (18) 9682 (8058, 11633) 0.05 
 
52 (13) 9787 (6576, 14566) 0.32 
 
221 (19) 9844 (7982, 12140) 0.08  0.87 
  ptrend   
0.05 
   
0.86 
   
0.02  0.13 
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Table 2. Associations between epidemiologic characteristics and anti-CA15.3 antibodies in healthy controls, stratified by menopausal status. (continued) 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
 
N (%) Mean (95% CI)* p 
Years since last birth  
           
  
  <21 404 (26) 8859 (7284, 10776) Ref. 
 
266 (69) 7034 (5863, 8439) Ref. 
 
133 (12) 10008 (7451, 13440) Ref.  Ref. 
  21-27   395 (26) 9545 (8194, 11118) 0.54 
 
95 (25) 8395 (6131, 11496) 0.37 
 
297 (26) 10571 (8766, 12747) 0.74  0.62 
  28-32 349 (23) 8407 (7130, 9912) 0.71 
 
22 (6) 12239 (6458, 23194) 0.11 
 
325 (29) 8632 (7286, 10225) 0.39  0.11 
  >32 382 (25) 7004 (5759, 8518) 0.16 
 
3 (1) 2878 (523, 15829) 0.31 
 
379 (33) 7318 (6074, 8817) 0.11  0.26 
  ptrend   
0.15 
   
0.27 
   
0.04  0.14 
  
           
  
Ovulatory cycles¶ 
           
  
  <= 368 380 (25) 8477 (7254, 9905) Ref. 
 
143 (34) 9521 (6598, 13739) Ref. 
 
236 (22) 8860 (7260, 10811) Ref.  Ref. 
  369-414 385 (25) 8147 (7006, 9474) 0.72 
 
120 (29) 9585 (7328, 12538) 0.98 
 
262 (24) 7540 (6251, 9095) 0.25  0.04 
  415-450 363 (24) 8097 (6929, 9460) 0.69 
 
80 (19) 4569 (3161, 6605) 0.02 
 
279 (25) 9236 (7701, 11077) 0.76  0.28 
  > 450 395 (26) 7839 (6740, 9117) 0.49 
 
73 (18) 4820 (3018, 7696) 0.07 
 
318 (29) 8468 (7138, 10046) 0.74  0.94 
  ptrend   
0.50 
   
0.02 
   
0.85  0.72 
  
           
  
Age at menopause (years) 
          
  
  ≤ 46  -- -- -- 
 
-- -- -- 
 
303 (27) 7982 (6676, 9542) Ref.   
  47 - 49  -- -- -- 
 
-- -- -- 
 
236 (21) 9052 (7417, 11048) 0.36   
  50 - 51  -- -- -- 
 
-- -- -- 
 
235 (21) 9521 (7794, 11631) 0.2   
  52 - 53  -- -- -- 
 
-- -- -- 
 
182 (16) 7948 (6334, 9972) 0.98   
  > 53  -- -- -- 
 
-- -- -- 
 
170 (15) 9450 (7441, 12000) 0.27   
  ptrend           
0.37   
  
           
  
Type of HRT 
           
  
  Never used HRT -- -- -- 
 
-- -- -- 
 
778 (75) 7931 (6792, 9260) Ref.   
  Estrogen alone -- -- -- 
 
-- -- -- 
 
81 (8) 13562 (8121, 22648) 0.18   
  Estrogen + Progestin -- -- -- 
 
-- -- -- 
 
177 (17) 9304 (6256, 13836) 0.82   
*Geometric means adjusted for matching factors, including study center (grouped by country), age at blood draw, fasting status, date and time of blood draw, menopausal status at blood draw, 
menstrual cycle phase for premenopausal women at blood draw, OC/HRT use at blood draw, length of follow up. HRT use adjusted for hysterectomy.  Age at menarche, OC use, parity, ovulatory cycles, 
hysterectomy, oophorectomy, menopausal status, age at menopause, and HRT use additionally adjusted for BMI and smoking status.  
† Trend including nulliparous women and those who never used oral contraceptives. 
§ Trend among parous women and OC users. 
¶Time between menarche and menopause with time subtracted for oral contraceptive use, pregnancy and breastfeeding; categories based on quartile cutpoints 
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Table 3. Associations between epidemiologic characteristics and anti-CA125 antibodies in healthy controls, stratified by menopausal status. 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p 
Age at blood draw (years)   
  
  
  
    
  < 41 75 (4) 5428 (4032, 7307) 0.04 
 
75 (15) 5494 (4136, 7298) 0.03 
 
0 (0)  --  --   
  41-50 327 (17) 3971 (3431, 4596) Ref. 
 
269 (55) 3827 (3326, 4404) Ref. 
 
47 (3) 4260 (3032, 5985) Ref.   
  51-60 853 (44) 4039 (3728, 4376) 0.85 
 
141 (29) 3852 (3098, 4790) 0.96 
 
697 (49) 4091 (3742, 4472) 0.82   
  61-70 585 (30) 4382 (3968, 4839) 0.31 
 
0 (0)  --  -- 
 
585 (41) 4436 (4028, 4885) 0.82   
  > 70 87 (5) 3812 (2939, 4946) 0.79 
 
0 (0)  --  -- 
 
87 (6) 3843 (2929, 5041) 0.64   
  ptrend   0.95 
 
  0.09 
 
  0.68   
     
 
   
 
     
BMI (kg/m2)    
 
   
 
     
  <18.5  30 (2) 4292 (2848, 6469) 0.92 
 
9 (2) 4366 (2088, 9129) 0.87 
 
21 (2) 3989 (2423, 6568) 0.79  0.56 
  18.5-24.99 872 (48) 4199 (3887, 4537) Ref. 
 
267 (59) 4104 (3592, 4690) Ref. 
 
589 (44) 4273 (3883, 4703) Ref.  Ref. 
  25 - 29.99 658 (36) 4131 (3784, 4510) 0.79 
 
131 (29) 4115 (3398, 4983) 0.98 
 
522 (39) 4158 (3762, 4596) 0.70  0.82 
  >=30 271 (15) 4087 (3548, 4708) 0.75 
 
46 (10) 3438 (2483, 4761) 0.33 
 
222 (16) 4246 (3615, 4987) 0.95  0.32 
  ptrend   0.71 
 
  0.4 
 
  0.95  0.27 
     
 
   
 
     
Smoking    
 
   
 
     
  Never 1096 (58) 4456 (4161, 4773) Ref. 
 
273 (57) 4301 (3764, 4914) Ref. 
 
816 (59) 4512 (4160, 4892) Ref.  Ref. 
  Former 431 (23) 4188 (3754, 4673) 0.35 
 
114 (24) 4184 (3387, 5169) 0.83 
 
310 (22) 4191 (3675, 4779) 0.36  0.64 
  Current 367 (19) 3348 (2973, 3772) <0.0001 
 
94 (20) 3271 (2593, 4127) 0.05 
 
266 (19) 3433 (2976, 3961) 0.001  0.99 
     
   
 
  
    
Packyears (among current smokers)   
   
 
  
    
  <=11 packyears 89 (25) 4703 (3778, 5854) Ref. 
 
34 (37) 3775 (2653, 5373) Ref. 
 
53 (21) 5060 (3777, 6778) Ref.  Ref. 
  12-19 91 (25) 3150 (2536, 3913) 0.01 
 
21 (23) 3228 (2044, 5097) 0.62 
 
67 (26) 3194 (2441, 4180) 0.03  0.68 
  20-31 95 (27) 2635 (2144, 3239) 0.0002 
 
26 (28) 2778 (1849, 4172) 0.29 
 
68 (26) 2834 (2203, 3644) 0.004  0.93 
  >31 82 (23) 2948 (2342, 3710) 0.005 
 
12 (13) 3104 (1722, 5596) 0.59 
 
69 (27) 2856 (2207, 3695) 0.004  0.40 
  ptrend 
 
 0.004 
 
  0.40 
 
  0.008  0.92 
    
 
   
 
     
Age at menarche (years)   
 
   
 
     
  < 12 266 (14) 4075 (3534, 4700) 0.81 
 
93 (20) 3889 (3071, 4924) 0.74 
 
171 (13) 4129 (3450, 4941) 0.98  0.80 
  12 352 (19) 3982 (3527, 4494) Ref. 
 
94 (20) 3677 (2911, 4644) Ref. 
 
257 (19) 4115 (3565, 4749) Ref.  Ref. 
  13 422 (23) 4234 (3792, 4727) 0.46 
 
118 (26) 4737 (3854, 5823) 0.12 
 
301 (22) 4082 (3577, 4657) 0.94  0.16 
  14 433 (24) 4042 (3623, 4509) 0.86 
 
94 (20) 4198 (3319, 5311) 0.44 
 
336 (25) 4027 (3553, 4564) 0.82  0.43 
  > 14 365 (20) 4362 (3868, 4920) 0.30 
 
60 (13) 3107 (2319, 4162) 0.38 
 
299 (22) 4696 (4107, 5370) 0.19  0.15 
  ptrend   0.47 
 
  0.64 
 
  0.28  0.35 
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Table 3. Associations between epidemiologic characteristics and anti-CA125 antibodies in healthy controls, stratified by menopausal status. (continued) 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p 
Oral contraceptive use    
 
   
 
     
  Never 924 (50) 4110 (3796, 4450) Ref. 
 
145 (31) 4657 (3814, 5686) Ref. 
 
775 (56) 4054 (3717, 4422) Ref.  Ref. 
  Ever 933 (50) 4167 (3850, 4510) 0.82 
 
320 (69) 3688 (3247, 4189) 0.07 
 
604 (44) 4404 (3985, 4867) 0.25  0.11 
     
 
   
 
     
  >= 2 years 257 (14) 4402 (3813, 5082) Ref. 
 
101 (22) 4565 (3624, 5750) Ref. 
 
153 (12) 4358 (3614, 5255) Ref.  Ref. 
  > 2 to 5 years 180 (10) 3534 (2979, 4193) 0.03 
 
68 (15) 3324 (2524, 4379) 0.10 
 
111 (8) 3580 (2871, 4463) 0.16  0.61 
  > 5  to 10 years 207 (12) 4059 (3453, 4771) 0.38 
 
77 (17) 3276 (2525, 4249) 0.07 
 
127 (10) 4487 (3642, 5529) 0.82  0.12 
  > 10 years 225 (13) 4360 (3716, 5115) 0.72 
 
62 (14) 3073 (2231, 4233) 0.09 
 
161 (12) 4903 (4059, 5923) 0.58  0.04 
  ptrend
†   0.57 
 
  0.04 
 
  0.07  0.13 
  ptrend
§   0.65 
 
  0.19 
 
  0.24  0.01 
     
 
   
 
     
Parity    
 
   
 
     
 Nulliparous 202 (11) 4376 (3740, 5120) Ref. 
 
48 (11) 3731 (2688, 5181) Ref. 
 
152 (12) 4582 (3815, 5503) Ref.  Ref. 
 Parous 1579 (89) 4124 (3900, 4361) 0.49 
 
406 (89) 3985 (3575, 4441) 0.71 
 
1162 (88) 4184 (3918, 4469) 0.36  0.50 
pdiff    
 
   
 
     
  1 child 277 (16) 3996 (3487, 4578) Ref. 
 
74 (17) 3535 (2710, 4612) Ref. 
 
200 (15) 4238 (3606, 4982) Ref.  Ref. 
  2 children 730 (42) 3994 (3674, 4341) 0.98 
 
215 (50) 4351 (3728, 5079) 0.24 
 
512 (40) 3852 (3483, 4261) 0.36  0.11 
  3 children 348 (20) 4565 (4048, 5148) 0.14 
 
75 (17) 4033 (3101, 5245) 0.59 
 
270 (21) 4718 (4111, 5414) 0.29  0.90 
  4+ children 180 (10) 4306 (3621, 5120) 0.49 
 
22 (5) 3646 (2221, 5986) 0.94 
 
157 (12) 4421 (3667, 5331) 0.74  0.90 
  ptrend
†   0.53 
 
  0.54 
 
  0.72  0.73 
  ptrend
§   0.15 
 
  0.84 
 
  0.20  0.82 
     
 
   
 
     
Age at first birth (years)   
 
   
 
     
  <20 120 (8) 3681 (2993, 4528) Ref. 
 
28 (7) 3624 (2334, 5628) Ref. 
 
90 (8) 3710 (2912, 4727) Ref.  Ref. 
  20-24 683 (43) 3978 (3651, 4335) 0.63 
 
179 (44) 3886 (3281, 4603) 0.77 
 
500 (43) 4082 (3689, 4516) 0.47  0.70 
  25-29 543 (34) 4277 (3884, 4711) 0.35 
 
140 (34) 4280 (3529, 5191) 0.50 
 
399 (34) 4184 (3734, 4688) 0.38  0.99 
  ≥30 228 (14) 4446 (3831, 5160) 0.23 
 
59 (15) 3674 (2711, 4979) 0.96 
 
168 (15) 4755 (3990, 5666) 0.11  0.38 
  ptrend   0.14 
 
  0.90 
 
  0.09  0.51 
     
 
   
 
     
Age at last birth (years)   
 
   
 
     
  <25 217 (14) 3567 (3056, 4164) Ref. 
 
64 (17) 4131 (3082, 5536) Ref. 
 
150 (13) 3419 (2838, 4118) Ref.  Ref. 
  25-29 532 (35) 4022 (3647, 4437) 0.21 
 
137 (35) 4330 (3552, 5279) 0.80 
 
394 (35) 3919 (3494, 4397) 0.22  0.79 
  30-34 508 (33) 4245 (3841, 4692) 0.09 
 
133 (34) 3571 (2931, 4352) 0.42 
 
369 (33) 4465 (3967, 5025) 0.02  0.06 
  ≥35 273 (18) 4772 (4152, 5483) 0.01 
 
52 (13) 4561 (3306, 6290) 0.66 
 
221 (19) 4833 (4137, 5645) 0.006  0.29 
  ptrend   0.01 
 
  0.78 
 
  0.002   
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Table 3. Associations between epidemiologic characteristics and anti-CA125 antibodies in healthy controls, stratified by menopausal status. (continued) 
 
  All 
 
Premenopausal 
 
Postmenopausal  
p-het 
  N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p   N (%) Mean (95% CI)* p 
Years since last birth    
 
   
 
     
  <21 404 (26) 4669 (4026, 5415) Ref. 
 
266 (69) 3896 (3364, 4513) Ref. 
 
133 (12) 5120 (4114, 6371) Ref.  Ref. 
  21-27   395 (26) 4455 (3969, 5001) 0.71 
 
95 (25) 4299 (3336, 5541) 0.53 
 
297 (26) 4710 (4100, 5411) 0.50  0.41 
  28-32 349 (23) 4129 (3645, 4677) 0.31 
 
22 (6) 5220 (3116, 8746) 0.30 
 
325 (29) 4214 (3717, 4778) 0.13  0.12 
  >32 382 (25) 3422 (2951, 3969) 0.02 
 
3 (1) 2797 (706, 11074) 0.64 
 
379 (33) 3529 (3074, 4052) 0.01  0.58 
  ptrend   0.03 
 
  0.42 
 
  0.005  0.10 
     
 
   
 
     
Ovulatory cycles¶    
 
   
 
     
  <= 368 380 (25) 4139 (3675, 4660) Ref. 
 
143 (34) 3661 (2722, 4924) Ref. 
 
236 (22) 4185 (3606, 4856) Ref.  Ref. 
  369-414 385 (25) 3994 (3560, 4481) 0.67 
 
120 (29) 4284 (3448, 5322) 0.42 
 
262 (24) 3844 (3342, 4423) 0.42  0.34 
  415-450 363 (24) 4083 (3626, 4598) 0.88 
 
80 (19) 3522 (2615, 4744) 0.88 
 
279 (25) 4356 (3803, 4990) 0.70  0.28 
  > 450 395 (26) 4374 (3898, 4908) 0.52 
 
73 (18) 5010 (3432, 7313) 0.30 
 
318 (29) 4395 (3868, 4994) 0.63  0.62 
  ptrend   0.48 
 
  0.44 
 
  0.36  0.91 
     
 
   
 
     
Age at menopause (years)   
 
   
 
     
  ≤ 46   --  --  -- 
 
 --  --  -- 
 
303 (27) 3993 (3495, 4562) Ref.   
  47 - 49   --  --  -- 
 
 --  --  -- 
 
236 (21) 3792 (3268, 4400) 0.61   
  50 - 51   --  --  -- 
 
 --  --  -- 
 
235 (21) 4576 (3941, 5313) 0.19   
  52 - 53   --  --  -- 
 
 --  --  -- 
 
182 (16) 4060 (3428, 4808) 0.88   
  > 53   --  --  -- 
 
 --  --  -- 
 
170 (15) 5009 (4192, 5986) 0.05   
  ptrend    
 
   
 
  0.08   
     
 
   
 
     
Type of HRT    
 
   
 
     
  Never used HRT  --  --  -- 
 
 --  --  -- 
 
778 (75) 4065 (3620, 4564) Ref.   
  Estrogen alone  --  --  -- 
 
 --  --  -- 
 
81 (8) 4992 (3402, 7325) 0.53   
  Estrogen + Progestin  --  --  --    --  --  --   177 (17) 4192 (3115, 5641) 0.88   
†Geometric means adjusted for matching factors, including study center (grouped by country), age at blood draw, fasting status, date and time of blood draw, menopausal status at blood, menstrual 
cycle phase for premenopausal women at blood, OC/HRT use at blood, length of follow up. HRT use adjusted for hysterectomy.  Age at menarche, OC use, parity, ovulatory cycles, hysterectomy, 
oophorectomy, menopausal status, age at menopause, and HRT use additionally adjusted for BMI and smoking status.  
† Trend including nulliparous women and those who never used oral contraceptives. 
§ Trend among parous women and OC users. 
¶Time between menarche and menopause with time subtracted for oral contraceptive use, pregnancy and breastfeeding; categories based on quartile cutpoints 
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Table 4. Associations between anti-CA15.3 and anti-CA125 antibodies and risk of ovarian cancer. 
 
  
All   <3 years between blood and diagnosis   ≥3 years between blood and diagnosis 
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
Anti-CA15.3 antibodies 
All EOC 
              
  Q1 481 (24.9) 218 (27.0) 1.00 (referent) 
  
170 (23.8) 56 (28.9) 1.00 (referent) 
  
311 (25.6) 162 (26.5) 1.00 (referent) 
 
  Q2 482 (25.0) 200 (24.8) 0.90 (0.71, 1.14) 0.39 
 
172 (24.1) 40 (20.6) 0.72 (0.45, 1.14) 0.16 
 
310 (25.6) 160 (26.1) 0.98 (0.74, 1.29) 0.88 
  Q3 484 (25.1) 175 (21.7) 0.80 (0.63, 1.01) 0.06 
 
168 (23.5) 45 (23.2) 0.83 (0.53, 1.30) 0.42 
 
316 (26.1) 130 (21.2) 0.78 (0.59, 1.04) 0.09 
  Q4 481 (24.9) 213 (26.4) 1.01 (0.80, 1.27) 0.93 
 
205 (28.7) 53 (27.3) 0.81 (0.52, 1.26) 0.34 
 
276 (22.8) 160 (26.1) 1.11 (0.84, 1.45) 0.47 
  p-trend 
   
0.62 
    
0.65 
    
0.20 
All EOC, premenopausal 
            
  Q1 129 (26.9) 51 (25.4) 1.00 (referent)  
 
50 (29.2) 12 (26.1) 1.00 (referent)  
 
79 (25.6) 39 (25.2) 1.00 (referent)  
  Q2 119 (24.8) 54 (26.9) 1.12 (0.71, 1.78) 0.63 
 
40 (23.4) 9 (19.6) 0.97 (0.38, 2.48) 0.95 
 
79 (25.6) 45 (29.0) 1.16 (0.68, 1.99) 0.58 
  Q3 118 (24.6) 47 (23.4) 1.00 (0.62, 1.59) 0.98 
 
40 (23.4) 9 (19.6) 1.04 (0.40, 2.68) 0.93 
 
78 (25.2) 38 (24.5) 0.98 (0.57, 1.69) 0.93 
  Q4 114 (23.8) 49 (24.4) 1.12 (0.70, 1.81) 0.63 
 
41 (24.0) 16 (34.8) 1.92 (0.79, 4.66) 0.15 
 
73 (23.6) 33 (21.3) 0.91 (0.52, 1.59) 0.74 
  p-trend 
   
0.88 
    
0.15 
    
0.55 
All EOC, postmenopausal   
   
  
   
  
  Q1 347 (24.6) 163 (27.7) 1.00 (referent)  
 
117 (22.0) 42 (29.0) 1.00 (referent)  
 
230 (26.2) 121 (27.3) 1.00 (referent)  
  Q2 351 (24.9) 144 (24.4) 0.87 (0.66, 1.15) 0.32 
 
129 (24.3) 31 (21.4) 0.67 (0.39, 1.16) 0.15 
 
222 (25.3) 113 (25.5) 0.95 (0.69, 1.31) 0.76 
  Q3 355 (25.2) 122 (20.7) 0.74 (0.56, 0.98) 0.03 
 
127 (23.9) 35 (24.1) 0.76 (0.45, 1.28) 0.31 
 
228 (26.0) 87 (19.6) 0.72 (0.52, 1.00) 0.05 
  Q4 356 (25.3) 160 (27.2) 0.99 (0.76, 1.30) 0.96 
 
158 (29.8) 37 (25.5) 0.64 (0.38, 1.09) 0.10 
 
198 (22.6) 123 (27.7) 1.18 (0.86, 1.61) 0.31 
  p-trend 
  
 0.60 
   
 0.28 
   
 0.09 
Serous cases 
 
  
   
  
   
  
  Q1 264 (24.8) 123 (27.8) 1.00 (referent)  
 
97 (24.3) 35 (32.4) 1.00 (referent)  
 
167 (25.2) 88 (26.3) 1.00 (referent)  
  Q2 244 (23.0) 109 (24.6) 0.96 (0.69, 1.32) 0.78 
 
91 (22.8) 21 (19.4) 0.65 (0.34, 1.22) 0.18 
 
153 (23.0) 88 (26.3) 1.09 (0.75, 1.59) 0.64 
  Q3 273 (25.7) 103 (23.3) 0.81 (0.59, 1.10) 0.18 
 
89 (22.3) 29 (26.9) 0.92 (0.52, 1.62) 0.77 
 
184 (27.7) 74 (22.1) 0.77 (0.53, 1.12) 0.17 
  Q4 282 (26.5) 108 (24.4) 0.85 (0.62, 1.16) 0.30 
 
122 (30.6) 23 (21.3) 0.51 (0.27, 0.96) 0.04 
 
160 (24.1) 85 (25.4) 1.02 (0.71, 1.48) 0.92 
  p-trend* 
  
 0.28 
   
 0.06 
   
 0.89 
Mucinous cases 
 
  
   
  
   
  
  Q1 41 (27.5) 15 (25.9) 1.00 (referent) 
  
18 (25.7) 7 (38.9) 1.00 (referent) 
  
23 (29.1) 8 (20.0) 1.00 (referent) 
 
  Q2 43 (28.9) 17 (29.3) 1.03 (0.46, 2.32) 0.94 
 
18 (25.7) 5 (27.8) 0.65 (0.18, 2.39) 0.52 
 
25 (31.6) 12 (30.0) 1.45 (0.52, 4.07) 0.48 
  Q3 43 (28.9) 11 (19.0) 0.67 (0.26, 1.70) 0.39 
 
20 (28.6) 2 (11.1) 0.21 (0.04, 1.26) 0.09 
 
23 (29.1) 9 (22.5) 1.27 (0.39, 4.10) 0.69 
  Q4 22 (14.8) 15 (25.9) 2.01 (0.78, 5.20) 0.15 
 
14 (20.0) 4 (22.2) 0.76 (0.18, 3.26) 0.71 
 
8 (10.1) 11 (27.5) 4.44 (1.16, 17.0) 0.03 
  p-trend* 
   
0.10 
    
0.93 
    
0.02 
Endometrioid cases 
             
  Q1 51 (22.3) 21 (21.9) 1.00 (referent) 
  
15 (16.9) 6 (24.0) 1.00 (referent) 
  
36 (25.7) 15 (21.1) 1.00 (referent) 
   Q2 68 (29.7) 24 (25.0) 0.85 (0.41, 1.76) 0.67 
 
29 (32.6) 4 (16.0) 0.36 (0.09, 1.47) 0.15 
 
39 (27.9) 20 (28.2) 1.23 (0.52, 2.90) 0.64 
  Q3 52 (22.7) 20 (20.8) 1.00 (0.47, 2.11) 0.99 
 
20 (22.5) 7 (28.0) 0.91 (0.26, 3.17) 0.88 
 
32 (22.9) 13 (18.3) 0.98 (0.39, 2.43) 0.96 
  Q4 58 (25.3) 31 (32.3) 1.37 (0.69, 2.71) 0.37 
 
25 (28.1) 8 (32.0) 0.88 (0.26, 2.96) 0.83 
 
33 (23.6) 23 (32.4) 1.68 (0.73, 3.86) 0.22 
  p-trend* 
  
 
0.21 
    
0.66 
    
0.19 
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Table 4. Associations between anti-CA15.3 and anti-CA125 antibodies and risk of ovarian cancer. (continued) 
  
All   <3 years between blood and diagnosis   ≥3 years between blood and diagnosis 
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
Anti-CA125 antibodies 
All EOC 
                Q1 480 (24.9) 213 (26.4) 1.00 (referent) 
  
167 (23.4) 46 (23.7) 1.00 (referent) 
  
313 (25.8) 167 (27.3) 1.00 (referent) 
 
  Q2 483 (25.1) 224 (27.8) 1.04 (0.82, 1.31) 0.75 
 
173 (24.2) 56 (28.9) 1.10 (0.70, 1.72) 0.68 
 
310 (25.6) 168 (27.5) 1.02 (0.77, 1.33) 0.91 
  Q3 481 (24.9) 169 (21.0) 0.80 (0.63, 1.02) 0.07 
 
176 (24.6) 36 (18.6) 0.76 (0.46, 1.24) 0.27 
 
305 (25.1) 133 (21.7) 0.81 (0.61, 1.07) 0.14 
  Q4 484 (25.1) 200 (24.8) 0.96 (0.76, 1.21) 0.70 
 
199 (27.8) 56 (28.9) 1.01 (0.65, 1.57) 0.96 
 
285 (23.5) 144 (23.5) 0.93 (0.71, 1.23) 0.63 
  p-trend 
   
0.52 
    
0.97 
    
0.72 
All EOC, premenopausal 
            
  Q1 124 (25.8) 50 (24.9) 1.00 (referent) 
  
47 (27.5) 11 (23.9) 1.00 (referent) 
  
77 (24.9) 39 (25.2) 1.00 (referent) 
 
  Q2 121 (25.2) 59 (29.4) 1.19 (0.74, 1.91) 0.47 
 
42 (24.6) 13 (28.3) 1.15 (0.46, 2.88) 0.76 
 
79 (25.6) 46 (29.7) 1.19 (0.68, 2.08) 0.53 
  Q3 113 (23.5) 40 (19.9) 0.86 (0.53, 1.40) 0.54 
 
38 (22.2) 5 (10.9) 0.59 (0.19, 1.83) 0.36 
 
75 (24.3) 35 (22.6) 0.92 (0.53, 1.59) 0.77 
  Q4 122 (25.4) 52 (25.9) 1.08 (0.68, 1.71) 0.75 
 
44 (25.7) 17 (37.0) 1.69 (0.73, 3.91) 0.22 
 
78 (25.2) 35 (22.6) 0.87 (0.50, 1.52) 0.63 
  p-trend 
   
0.97 
    
0.21 
    
0.48 
All EOC, postmenopausal   
   
  
   
  
  Q1 345 (24.5) 160 (27.2) 1.00 (referent)  
 
117 (22.0) 35 (24.1) 1.00 (referent)  
 
228 (26.0) 125 (28.2) 1.00 (referent)  
  Q2 356 (25.3) 161 (27.3) 0.97 (0.74, 1.27) 0.83 
 
130 (24.5) 41 (28.3) 0.99 (0.58, 1.67) 0.96 
 
226 (25.7) 120 (27.0) 0.96 (0.70, 1.32) 0.81 
  Q3 358 (25.4) 128 (21.7) 0.78 (0.59, 1.04) 0.09 
 
136 (25.6) 31 (21.4) 0.77 (0.45, 1.33) 0.35 
 
222 (25.3) 97 (21.8) 0.78 (0.56, 1.09) 0.15 
  Q4 350 (24.8) 140 (23.8) 0.88 (0.67, 1.16) 0.36 
 
148 (27.9) 38 (26.2) 0.82 (0.48, 1.39) 0.46 
 
202 (23.0) 102 (23.0) 0.90 (0.65, 1.25) 0.55 
  p-trend 
   
0.34 
    
0.52 
    
0.72 
Serous cases 
             
  Q1 268 (25.2) 117 (26.4) 1.00 (referent) 
  
99 (24.8) 25 (23.1) 1.00 (referent) 
  
169 (25.5) 92 (27.5) 1.00 (referent) 
 
  Q2 258 (24.3) 128 (28.9) 1.13 (0.83, 1.55) 0.44 
 
98 (24.6) 30 (27.8) 1.13 (0.61, 2.09) 0.69 
 
160 (24.1) 98 (29.3) 1.14 (0.79, 1.64) 0.49 
  Q3 246 (23.1) 89 (20.1) 0.84 (0.61, 1.17) 0.31 
 
89 (22.3) 21 (19.4) 0.96 (0.50, 1.86) 0.91 
 
157 (23.6) 68 (20.3) 0.81 (0.55, 1.18) 0.27 
  Q4 291 (27.4) 109 (24.6) 0.87 (0.63, 1.19) 0.37 
 
113 (28.3) 32 (29.6) 1.10 (0.61, 1.99) 0.75 
 
178 (26.8) 77 (23.0) 0.79 (0.54, 1.14) 0.21 
  p-trend† 
   
0.17 
    
0.85 
    
0.11 
Mucinous cases 
             
  Q1 45 (30.2) 12 (20.7) 1.00 (referent) 
  
20 (28.6) 4 (22.2) 1.00 (referent) 
  
25 (31.6) 8 (20.0) 1.00 (referent) 
 
  Q2 34 (22.8) 15 (25.9) 1.68 (0.67, 4.21) 0.27 
 
14 (20.0) 5 (27.8) 1.61 (0.38, 6.73) 0.52 
 
20 (25.3) 10 (25.0) 1.74 (0.53, 5.71) 0.36 
  Q3 46 (30.9) 17 (29.3) 1.44 (0.59, 3.57) 0.42 
 
21 (30.0) 5 (27.8) 1.15 (0.29, 4.58) 0.84 
 
25 (31.6) 12 (30.0) 1.74 (0.53, 5.79) 0.36 
  Q4 24 (16.1) 14 (24.1) 2.52 (0.95, 6.67) 0.06 
 
15 (21.4) 4 (22.2) 1.37 (0.29, 6.45) 0.69 
 
9 (11.4) 10 (25.0) 3.84 (1.06, 13.9) 0.04 
  p-trend† 
  
 0.15 
   
 0.93 
   
 0.05 
Endometrioid cases 
             
  Q1 52 (22.7) 27 (28.1) 1.00 (referent) 
  
18 (20.2) 7 (28.0) 1.00 (referent) 
  
34 (24.3) 20 (28.2) 1.00 (referent) 
   Q2 68 (29.7) 23 (24.0) 0.60 (0.30, 1.21) 0.16 
 
24 (27.0) 5 (20.0) 0.49 (0.13, 1.77) 0.27 
 
44 (31.4) 18 (25.4) 0.67 (0.29, 1.53) 0.34 
  Q3 55 (24.0) 19 (19.8) 0.67 (0.33, 1.37) 0.27 
 
20 (22.5) 5 (20.0) 0.62 (0.15, 2.49) 0.50 
 
35 (25.0) 14 (19.7) 0.69 (0.30, 1.60) 0.39 
  Q4 54 (23.6) 27 (28.1) 1.07 (0.54, 2.11) 0.84 
 
27 (30.3) 8 (32.0) 0.83 (0.26, 2.65) 0.75 
 
27 (19.3) 19 (26.8) 1.24 (0.54, 2.86) 0.62 
  p-trend†       0.54         0.96         0.31 
*p-heterogeneity comparing trend across serous, mucinous and endometrioid histologic types: all, p=0.06; <3 years, p=0.42, ≥3 years, p=0.07. 
†
p-heterogeneity comparing trend across serous, mucinous and endometrioid histologic types: all, p=0.08; <3 years, p=0.99, ≥3 years, p=0.03. 
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Table 5. Association between anti-CA15.3 and anti-CA125 antibodies in perspective of CA15.3 and CA125 level. 
 
Antigen/ 
antibody 
combinations 
All   <3 years between blood and diagnosis   ≥3 years between blood and diagnosis 
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
CA15.3/anti-CA15.3 antibodies 
All EOC 
              
   Low/low 457 (23.8) 207 (25.7) 1.00 (referent) 
  
168 (23.7) 44 (22.8) 1.00 (referent) 
  
289 (23.9) 163 (26.7) 1.00 (referent) 
 
   High/low  502 (26.2) 210 (26.1) 0.93 (0.74, 1.18) 0.57 
 
172 (24.3) 51 (26.4) 1.20 (0.75, 1.90) 0.45 
 
330 (27.3) 159 (26.0) 0.86 (0.65, 1.13) 0.26 
   Low/high 503 (26.2) 184 (22.9) 0.83 (0.66, 1.05) 0.13 
 
200 (28.2) 45 (23.3) 0.90 (0.57, 1.44) 0.66 
 
303 (25.0) 139 (22.7) 0.82 (0.62, 1.07) 0.14 
   High/high 457 (23.8) 203 (25.2) 1.00 (0.79, 1.27) 0.99 
 
169 (23.8) 53 (27.5) 1.23 (0.77, 1.97) 0.38 
 
288 (23.8) 150 (24.5) 0.93 (0.71, 1.22) 0.61 
All EOC, premenopausal 
             
   Low/low 133 (27.8) 56 (27.9) 1.00 (referent) 
  
48 (28.2) 7 (15.2) 1.00 (referent) 
  
85 (27.5) 49 (31.6) 1.00 (referent) 
 
   High/low  114 (23.8) 49 (24.4) 1.02 (0.64, 1.62) 0.93 
 
41 (24.1) 14 (30.4) 2.01 (0.74, 5.47) 0.17 
 
73 (23.6) 35 (22.6) 0.84 (0.49, 1.43) 0.51 
   Low/high 132 (27.6) 55 (27.4) 1.01 (0.65, 1.58) 0.95 
 
43 (25.3) 16 (34.8) 2.69 (1.01, 7.14) 0.05 
 
89 (28.8) 39 (25.2) 0.76 (0.45, 1.26) 0.28 
   High/high 100 (20.9) 41 (20.4) 1.00 (0.62, 1.63) 0.99 
 
38 (22.4) 9 (19.6) 1.63 (0.56, 4.72) 0.37 
 
62 (20.1) 32 (20.6) 0.90 (0.51, 1.59) 0.72 
All EOC, postmenopausal 
             
   Low/low 318 (22.7) 149 (25.4) 1.00 (referent) 
  
118 (22.4) 37 (25.7) 1.00 (referent) 
  
200 (22.9) 112 (25.3) 1.00 (referent) 
 
   High/low  377 (26.9) 157 (26.7) 0.90 (0.68, 1.19) 0.45 
 
127 (24.1) 35 (24.3) 0.97 (0.57, 1.66) 0.92 
 
250 (28.6) 122 (27.5) 0.87 (0.63, 1.21) 0.41 
   Low/high 357 (25.5) 124 (21.1) 0.77 (0.58, 1.02) 0.06 
 
152 (28.9) 28 (19.4) 0.61 (0.35, 1.06) 0.08 
 
205 (23.4) 96 (21.7) 0.84 (0.61, 1.17) 0.3 
   High/high 349 (24.9) 157 (26.7) 0.98 (0.75, 1.29) 0.88 
 
129 (24.5) 44 (30.6) 1.13 (0.66, 1.91) 0.66 
 
220 (25.1) 113 (25.5) 0.93 (0.67, 1.27) 0.63 
Serous cases 
              
   Low/low 249 (23.6) 124 (28.0) 1.00 (referent) 
  
100 (25.3) 23 (21.3) 1.00 (referent) 
  
149 (22.5) 101 (30.1) 1.00 (referent) 
 
   High/low  257 (24.3) 108 (24.4) 0.83 (0.60, 1.15) 0.27 
 
88 (22.2) 33 (30.6) 1.66 (0.90, 3.07) 0.11 
 
169 (25.6) 75 (22.4) 0.64 (0.43, 0.93) 0.02 
   Low/high 288 (27.2) 113 (25.5) 0.80 (0.59, 1.09) 0.16 
 
108 (27.3) 32 (29.6) 1.30 (0.71, 2.39) 0.39 
 
180 (27.2) 81 (24.2) 0.67 (0.47, 0.96) 0.03 
   High/high* 263 (24.9) 98 (22.1) 0.75 (0.54, 1.03) 0.08 
 
100 (25.3) 20 (18.5) 0.85 (0.43, 1.68) 0.64 
 
163 (24.7) 78 (23.3) 0.71 (0.49, 1.03) 0.07 
Mucinous cases 
             
   Low/low 38 (25.5) 14 (24.1) 1.00 (referent) 
  
11 (15.7) 5 (27.8) 1.00 (referent) 
  
27 (34.2) 9 (22.5) 1.00 (referent) 
 
   High/low  46 (30.9) 18 (31.0) 1.25 (0.54, 2.90) 0.61 
 
25 (35.7) 7 (38.9) 0.53 (0.12, 2.32) 0.40 
 
21 (26.6) 11 (27.5) 1.53 (0.54, 4.37) 0.42 
   Low/high 34 (22.8) 9 (15.5) 0.78 (0.30, 2.03) 0.61 
 
16 (22.9) 2 (11.1) 0.26 (0.04, 1.66) 0.15 
 
18 (22.8) 7 (17.5) 1.12 (0.35, 3.63) 0.84 
   High/high* 31 (20.8) 17 (29.3) 1.64 (0.69, 3.92) 0.26 
 
18 (25.7) 4 (22.2) 0.43 (0.09, 2.06) 0.29 
 
13 (16.5) 13 (32.5) 3.00 (0.99, 9.08) 0.05 
Endometrioid cases 
             
   Low/low 62 (27.2) 18 (18.9) 1.00 (referent) 
  
20 (22.7) 6 (25.0) 1.00 (referent) 
  
42 (30.0) 12 (16.9) 1.00 (referent) 
 
   High/low  56 (24.6) 26 (27.4) 1.66 (0.82, 3.37) 0.16 
 
23 (26.1) 3 (12.5) 0.49 (0.10, 2.28) 0.36 
 
33 (23.6) 23 (32.4) 2.42 (1.04, 5.62) 0.04 
   Low/high 64 (28.1) 24 (25.3) 1.41 (0.69, 2.86) 0.35 
 
27 (30.7) 4 (16.7) 0.51 (0.12, 2.20) 0.37 
 
37 (26.4) 20 (28.2) 1.91 (0.83, 4.41) 0.13 
   High/high* 46 (20.2) 27 (28.4) 2.22 (1.06, 4.68) 0.04 
 
18 (20.5) 11 (45.8) 1.96 (0.59, 6.58) 0.27 
 
28 (20.0) 16 (22.5) 2.03 (0.80, 5.17) 0.14 
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Table 5. Association between anti-CA15.3 and anti-CA125 antibodies in perspective of CA15.3 and CA125 level. (continued) 
 
Antigen/ 
antibody 
combinations 
All   <3 years between blood and diagnosis   ≥3 years between blood and diagnosis 
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
  
Controls 
N (%) 
Cases  
N (%) 
OR (95% CI) p 
CA125 / anti-CA125 antibodies 
All EOC 
                 Low/low 481 (25.0) 196 (24.3) 1.00 (referent) 
  
174 (24.4) 31 (16.0) 1.00 (referent) 
  
307 (25.3) 165 (27.0) 1.00 (referent) 
 
   High/low  479 (24.9) 241 (29.9) 1.30 (1.03, 1.64) 0.03 
 
164 (23.0) 71 (36.6) 2.67 (1.63, 4.35) <0.0001 
 
315 (26.0) 170 (27.8) 1.02 (0.78, 1.34) 0.88 
   Low/high 483 (25.1) 138 (17.1) 0.71 (0.55, 0.91) 0.01 
 
192 (26.9) 18 (9.3) 0.54 (0.29, 1.01) 0.05 
 
291 (24.0) 120 (19.6) 0.75 (0.56, 1.00) 0.05 
   High/high 483 (25.1) 231 (28.7) 1.26 (0.99, 1.60) 0.06 
 
183 (25.7) 74 (38.1) 2.48 (1.53, 4.00) 0.0002 
 
300 (24.7) 157 (25.7) 0.98 (0.74, 1.30) 0.91 
All EOC, premenopausal 
             
   Low/low 80 (16.7) 34 (16.9) 1.00 (referent) 
  
30 (17.5) 9 (19.6) 1.00 (referent) 
  
50 (16.2) 25 (16.1) 1.00 (referent) 
 
   High/low  165 (34.4) 75 (37.3) 1.07 (0.65, 1.78) 0.79 
 
59 (34.5) 15 (32.6) 0.91 (0.35, 2.36) 0.84 
 
106 (34.3) 60 (38.7) 1.16 (0.64, 2.10) 0.64 
   Low/high 73 (15.2) 21 (10.4) 0.65 (0.34, 1.25) 0.2 
 
25 (14.6) 2 (4.3) 0.26 (0.05, 1.37) 0.11 
 
48 (15.5) 19 (12.3) 0.78 (0.38, 1.63) 0.51 
   High/high 162 (33.8) 71 (35.3) 1.07 (0.64, 1.77) 0.81 
 
57 (33.3) 20 (43.5) 1.33 (0.53, 3.33) 0.54 
 
105 (34.0) 51 (32.9) 0.98 (0.53, 1.80) 0.95 
All EOC, postmenopausal 
             
   Low/low 393 (27.9) 158 (26.8) 1.00 (referent) 
  
143 (27.0) 22 (15.2) 1.00 (referent) 
  
250 (28.5) 136 (30.6) 1.00 (referent) 
 
   High/low  305 (21.7) 163 (27.7) 1.38 (1.06, 1.81) 0.02 
 
102 (19.3) 54 (37.2) 3.69 (2.06, 6.60) <0.0001 
 
203 (23.1) 109 (24.5) 1.00 (0.73, 1.36) 0.99 
   Low/high 405 (28.8) 115 (19.5) 0.71 (0.54, 0.95) 0.02 
 
166 (31.4) 16 (11.0) 0.66 (0.34, 1.31) 0.24 
 
239 (27.2) 99 (22.3) 0.75 (0.54, 1.02) 0.07 
   High/high 304 (21.6) 153 (26.0) 1.32 (1.00, 1.74) 0.05 
 
118 (22.3) 53 (36.6) 2.95 (1.67, 5.20) 0.0002 
 
186 (21.2) 100 (22.5) 0.99 (0.71, 1.37) 0.95 
Serous cases 
              
   Low/low 247 (23.3) 108 (24.4) 1.00 (referent) 
  
104 (26.2) 14 (13.0) 1.00 (referent) 
  
143 (21.5) 94 (28.1) 1.00 (referent) 
 
   High/low  276 (26.0) 137 (30.9) 1.16 (0.85, 1.58) 0.35 
 
91 (22.9) 41 (38.0) 3.91 (1.92, 7.96) 0.0002 
 
185 (27.9) 96 (28.7) 0.80 (0.55, 1.15) 0.22 
   Low/high 260 (24.5) 73 (16.5) 0.64 (0.45, 0.91) 0.01 
 
106 (26.7) 12 (11.1) 0.84 (0.37, 1.89) 0.68 
 
154 (23.2) 61 (18.2) 0.60 (0.40, 0.89) 0.01 
   High/high† 278 (26.2) 125 (28.2) 1.07 (0.77, 1.46) 0.70 
 
96 (24.2) 41 (38.0) 3.51 (1.76, 7.02) 0.0004 
 
182 (27.4) 84 (25.1) 0.71 (0.49, 1.03) 0.07 
Mucinous cases 
             
   Low/low 36 (24.2) 11 (19.0) 1.00 (referent) 
  
12 (17.1) 6 (33.3) 1.00 (referent) 
  
24 (30.4) 5 (12.5) 1.00 (referent) 
 
   High/low  43 (28.9) 16 (27.6) 1.37 (0.51, 3.68) 0.53 
 
22 (31.4) 3 (16.7) 0.22 (0.04, 1.20) 0.08 
 
21 (26.6) 13 (32.5) 3.80 (1.00, 14.46) 0.05 
   Low/high 33 (22.1) 9 (15.5) 0.97 (0.35, 2.70) 0.95 
 
15 (21.4) 1 (5.6) 0.12 (0.01, 1.17) 0.07 
 
18 (22.8) 8 (20.0) 2.57 (0.68, 9.66) 0.16 
   High/high† 37 (24.8) 22 (37.9) 2.34 (0.91, 6.03) 0.08 
 
21 (30.0) 8 (44.4) 0.65 (0.16, 2.56) 0.54 
 
16 (20.3) 14 (35.0) 5.45 (1.42, 20.98) 0.01 
Endometrioid cases 
             
   Low/low 65 (28.4) 21 (21.9) 1.00 (referent) 
  
24 (27.0) 3 (12.0) 1.00 (referent) 
  
41 (29.3) 18 (25.4) 1.00 (referent) 
 
   High/low  55 (24.0) 29 (30.2) 1.78 (0.89, 3.54) 0.1 
 
18 (20.2) 9 (36.0) 3.67 (0.91, 14.82) 0.07 
 
37 (26.4) 20 (28.2) 1.29 (0.58, 2.91) 0.53 
   Low/high 59 (25.8) 20 (20.8) 1.10 (0.53, 2.30) 0.8 
 
28 (31.5) 4 (16.0) 1.04 (0.21, 5.25) 0.96 
 
31 (22.1) 16 (22.5) 1.21 (0.52, 2.82) 0.66 
   High/high† 50 (21.8) 26 (27.1) 1.87 (0.90, 3.87) 0.09   19 (21.3) 9 (36.0) 4.06 (0.92, 17.86) 0.06   31 (22.1) 17 (23.9) 1.33 (0.57, 3.13) 0.51 
*p-heterogeneity for high/high vs. low/low across serous, mucinous and endometrioid histologic types: all, p=0.01; <3 years, p=0.29; ≥3 years, p=0.01. 
†p-heterogeneity for high/high vs. low/low across serous, mucinous and endometrioid histologic types: all, p=0.15; <3 years, p=0.08; ≥3 years, p=0.01. 
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Table 6. Spearman partial correlations between antigens and antibodies, stratified by menopausal status in EPIC cases 
and controls. 
      All   Premenopausal   Postmenopausal 
      N r* p   N r* p   N r* p 
CA15.3 and anti-CA15.3 antibodies 
Cases All 
 
804 -0.04 0.30 
 
201 -0.15 0.04 
 
587 -0.02 0.68 
              
 
Serous 
 
443 -0.05 0.32 
 
109 -0.34 0.001 
 
326 0.03 0.64 
 
Mucinous 
 
58 0.11 0.49 
 
20 0.24 0.70 
 
37 0.11 0.61 
 
Endometrioid 
 
95 -0.07 0.52 
 
29 -0.04 0.88 
 
62 -0.05 0.72 
              
 
<1 year 
 
61 -0.05 0.73 
 
19 -0.35 0.56 
 
42 0.06 0.74 
 
>1-3 years 
 
132 0.09 0.36 
 
27 0.28 0.40 
 
102 0.06 0.59 
 
>3-6 years 
 
199 -0.17 0.02 
 
40 -0.05 0.83 
 
156 -0.18 0.04 
 
>6-9 years 
 
194 0.01 0.87 
 
65 -0.05 0.72 
 
124 0.06 0.55 
 
>9 years 
 
218 -0.01 0.94 
 
50 -0.13 0.48 
 
163 0.04 0.67 
              Controls n/a 
 
1918 -0.04 0.06 
 
484 -0.06 0.22 
 
1408 -0.03 0.20 
              CA125 and anti-CA125 antibodies 
Cases All 
 
806 0.10 0.004 
 
201 0.14 0.05 
 
589 0.08 0.05 
              
 
Serous 
 
443 0.10 0.04 
 
109 0.22 0.03 
 
326 0.08 0.14 
 
Mucinous 
 
58 0.40 0.01 
 
20 0.47 0.43 
 
37 0.54 0.005 
 
Endometrioid 
 
96 0.18 0.12 
 
29 -0.19 0.52 
 
63 0.07 0.62 
              
 
<1 year 
 
61 -0.21 0.17 
 
19 0.49 0.41 
 
42 -0.34 0.08 
 
>1-3 years 
 
133 0.22 0.02 
 
27 -0.23 0.50 
 
103 0.19 0.07 
 
>3-6 years 
 
199 0.04 0.58 
 
40 0.10 0.64 
 
156 0.02 0.83 
 
>6-9 years 
 
195 0.11 0.13 
 
65 0.18 0.22 
 
125 0.16 0.09 
 
>9 years 
 
218 0.05 0.50 
 
50 -0.25 0.16 
 
163 0.03 0.73 
              Controls n/a   1925 0.01 0.81   485 <0.01 0.99   1414 0.01 0.73 
*Adjusted for matching factors, including age at blood draw, fasting status, date and time of blood draw, menopausal status at blood, 
menstrual cycle phase for premenopausal women at blood, OC/HRT use at blood, length of follow up.  
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